Search

Abstract submission

The official abstract submission is now closed.

Read more

Meeting Program

For the program please click here.  

If you would like a printable / PDF version of the program, you can download it via the 'Scientific Programme' tab in the above linked planner.

Read more

Highlights of Past EHA (HOPE) Latin America (LA) 2023 - report

October 26, 2023 – São Paulo, Brazil

Meeting chairs:

A Almeida - President EHA

JF Comenalli Marques Jr - President ABHH

C Chiattone - President HEMO 2023

This year, the HOPE LA meeting was held in collaboration with the Associação Brasileira de Hematologia Hemoterapia e…

Read more

Connecting experts on inherited anemias and iron defects in Budapest

October 12-14, 2023 – Budapest, Hungary 

Meeting Chairs: 
Ali Taher, American University of Beirut Medical Center, Beirut, Lebanon 

Achille Iolascon, University Federico II of Naples, Naples, Italy 

In October 2023 EHA and the Specialized Working Group (SWG) on Red Cell and Iron hosted a…

Read more

Abstract submission & Awards

Abstract and Case Report submission is now closed. Abstract awardsIntroduced in 2021 and after 3 editions, we are excited to announce the 4th Emerging Investigators EHA-EBMT Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy 2024.

Read more

Nurses abstract submission

Abstract and Case Report submission for nurses is now closed. Nurses abstract submissionDon’t miss out on a great opportunity to submit an abstract for the 6th EHA-EBMT European CAR T-cell Meeting 2024.

Read more

Commonalities and Differences in Myeloid Malignancies: Insights from the EHA-SWG Scientific Meeting on MDS, MPN, and AML

November 2-4 - Budapest, Hungary

Meeting Chairs:

Konstanze Döhner, University Hospital Ulm, Germany
Claire Harrison, Guy's and St.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

Meeting Program

EHA-SfPM Precision Medicine



Read more